These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 30733690)

  • 1. Glutamatergic Dysfunction and Glutamatergic Compounds for Major Psychiatric Disorders: Evidence From Clinical Neuroimaging Studies.
    Li CT; Yang KC; Lin WC
    Front Psychiatry; 2018; 9():767. PubMed ID: 30733690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological properties of glutamatergic drugs targeting NMDA receptors and their application in major depression.
    Serafini G; Pompili M; Innamorati M; Dwivedi Y; Brahmachari G; Girardi P
    Curr Pharm Des; 2013; 19(10):1898-922. PubMed ID: 23173582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
    Naughton M; Clarke G; O'Leary OF; Cryan JF; Dinan TG
    J Affect Disord; 2014 Mar; 156():24-35. PubMed ID: 24388038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of glutamate receptors and glial cells in the pathophysiology of treatment-resistant depression.
    Kim YK; Na KS
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Oct; 70():117-26. PubMed ID: 27046518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New Treatment Strategies of Depression: Based on Mechanisms Related to Neuroplasticity.
    Huang YJ; Lane HY; Lin CH
    Neural Plast; 2017; 2017():4605971. PubMed ID: 28491480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The glutamate hypothesis of schizophrenia: neuroimaging and drug development.
    Egerton A; Stone JM
    Curr Pharm Biotechnol; 2012 Jun; 13(8):1500-12. PubMed ID: 22283750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review.
    Iadarola ND; Niciu MJ; Richards EM; Vande Voort JL; Ballard ED; Lundin NB; Nugent AC; Machado-Vieira R; Zarate CA
    Ther Adv Chronic Dis; 2015 May; 6(3):97-114. PubMed ID: 25954495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glutamate Signaling in Synaptogenesis and NMDA Receptors as Potential Therapeutic Targets for Psychiatric Disorders.
    Ohgi Y; Futamura T; Hashimoto K
    Curr Mol Med; 2015; 15(3):206-21. PubMed ID: 25817855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments.
    Kadriu B; Musazzi L; Henter ID; Graves M; Popoli M; Zarate CA
    Int J Neuropsychopharmacol; 2019 Feb; 22(2):119-135. PubMed ID: 30445512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imaging the glutamatergic system in vivo--relevance to schizophrenia.
    Bressan RA; Pilowsky LS
    Eur J Nucl Med; 2000 Nov; 27(11):1723-31. PubMed ID: 11105831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene expression related to serotonergic and glutamatergic neurotransmission is altered in the flinders sensitive line rat model of depression: Effect of ketamine.
    Du Jardin KG; Müller HK; Sanchez C; Wegener G; Elfving B
    Synapse; 2017 Jan; 71(1):37-45. PubMed ID: 27589698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glutamatergic Signaling Drives Ketamine-Mediated Response in Depression: Evidence from Dynamic Causal Modeling.
    Gilbert JR; Yarrington JS; Wills KE; Nugent AC; Zarate CA
    Int J Neuropsychopharmacol; 2018 Aug; 21(8):740-747. PubMed ID: 29668918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of glutamate on the action of antidepressants.
    Hashimoto K
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Aug; 35(7):1558-68. PubMed ID: 20600468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid-onset antidepressant efficacy of glutamatergic system modulators: the neural plasticity hypothesis of depression.
    Wang J; Jing L; Toledo-Salas JC; Xu L
    Neurosci Bull; 2015 Feb; 31(1):75-86. PubMed ID: 25488282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ketamine in Major Depressive Disorder: Mechanisms and Future Perspectives.
    Shin C; Kim YK
    Psychiatry Investig; 2020 Mar; 17(3):181-192. PubMed ID: 32209965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ketamine for Treatment-Resistant Depression: a New Advocate.
    Pérez-Esparza R
    Rev Invest Clin; 2018; 70(2):65-7. PubMed ID: 29718013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Roles of glutamate signaling in preclinical and/or mechanistic models of depression.
    Tokita K; Yamaji T; Hashimoto K
    Pharmacol Biochem Behav; 2012 Feb; 100(4):688-704. PubMed ID: 21536063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine].
    Mechri A; Saoud M; Khiari G; d'Amato T; Dalery J; Gaha L
    Encephale; 2001; 27(1):53-9. PubMed ID: 11294039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fast-acting antidepressant activity of ketamine: highlights on brain serotonin, glutamate, and GABA neurotransmission in preclinical studies.
    Pham TH; Gardier AM
    Pharmacol Ther; 2019 Jul; 199():58-90. PubMed ID: 30851296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imaging the glutamate system in humans: relevance to drug discovery for schizophrenia.
    Stone JM
    Curr Pharm Des; 2009; 15(22):2594-602. PubMed ID: 19689330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.